Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.
Standaert
David G
DG
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. standaert@helix.mgh.harvard.edu
D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects / Q000503:physiopathology; D018491:Dopamine Agonists / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control; D004525:Efferent Pathways / Q000187:drug effects / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology*; D043705:Receptor, Adenosine A2A / Q000187:drug effects / Q000378:metabolism*
D018491:Dopamine Agonists; D004791:Enzyme Inhibitors; D043705:Receptor, Adenosine A2A; D007980:Levodopa